21:31 , Dec 2, 2016 |  BioCentury  |  Emerging Company Profile

Passing CARs

CAR T therapies have produced profound responses in hematological cancers, but also severe toxicities such as cytokine release syndrome. Triumvira Immunologics Inc.’s T Cell-Antigen Coupler platform combines the specificity of chimeric antigen receptors with the...
07:00 , Mar 19, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: CXC chemokine receptor 4 (CXCR4; NPY3R); lymphocyte-specific protein kinase (LCK) Provisional patent application filed; available for licensing

Autoimmune disease INDICATION: Autoimmune disease In vitro studies suggest an antibody-drug conjugate (ADC) targeting CXCR4 and LCK could help treat autoimmune diseases. In a human cell line, a humanized antibody against CXCR4 bound T cells with a...
07:00 , Oct 24, 2011 |  BioCentury  |  Product Development

Kinase by kinase in PAH

In the span of three weeks, cancer drugs Gleevec imatinib and Sprycel dasatinib have shown divergent signals in pulmonary arterial hypertension. Gleevec met the primary endpoint of treating PAH symptoms in a Phase III trial,...
07:00 , Apr 23, 2007 |  BioCentury  |  Tools & Techniques

High probability pathways

High probability pathways Pathway Genes in pathway (A) Pathway components [Ranking] (A) [5] Fibroblast growth factor (FGF) signaling MAP2K4; FGFR4; FGFR1; MAPK14; MAPK8; MAPK9; FGFR3; MAP3K6; MAP3K2; MAPK11; PRKCB1; RAF1; PRKCA; PRKCH; MAPK13; AKT3; PRKCE;...
08:00 , Feb 27, 2006 |  BioCentury  |  Product Development

Targeted =/ narrow

A great deal of nonsense has been written about molecular medicine. This ranges on the one hand from puff pieces claiming that targeted therapeutics will provide the perfect drugs to cure every patient without side...
07:00 , Sep 9, 2002 |  BioCentury  |  Emerging Company Profile

Signase: Src revival

The current popularity of kinases seems to have vindicated Andy Warhol's dictum that just about everyone gets to enjoy 15 minutes of fame. Almost every new addition to the kinase superfamily is touted as the...
07:00 , Jul 1, 2002 |  BC Week In Review  |  Company News

Molecular Devices sales and marketing update

Molecular Devices Corp. (MDCC), Sunnyvale, Calif.   Business: High throughput screening   MDCC launched six assay kits for use with its IMAP kinase inhibitor screening technology: PRAK, MSK1; Src, Fyn, Lck and PP2A....
08:00 , Jan 17, 2000 |  BioCentury  |  Emerging Company Profile

Kinetix: Structural themes

Members of any single family of enzymes in the body share a structural basis, a scaffold around which individual family member shapes vary. Kinetix Pharmaceuticals Inc. has taken advantage of the structural themes running through...
08:00 , Dec 20, 1993 |  BC Week In Review  |  Company News

University of Washington other research news

A transgenic mouse, which inappropriately expresses interleukin-4, develops a thinning of bone that resembles human osteoporosis, according to university scientists. The disease in the mice appears to result from decreased bone formation by the osteoblast...